LAUSANNE, Switzerland - ADC Therapeutics SA (NYSE:ADCT) reported promising initial results from a Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory marginal zone lymphoma (MZL).
The trial, conducted at the Sylvester Comprehensive Cancer Center at the University of Miami and City of Hope, showed that out of 15 evaluable patients, 13 achieved a complete response and one achieved a partial response.
The study is evaluating the safety and efficacy of six cycles of ZYNLONTA over 18 weeks in patients with MZL who have been previously treated with at least one line of systemic therapy. All patients who responded to the treatment maintained their responses at the data cutoff date.
The treatment was generally well-tolerated, with safety profiles consistent with previous findings. Two patients discontinued treatment due to toxicity but remained in complete response for 10 and 6 months, respectively.
These initial findings were presented at the Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Scientific Workshop. Dr. Izidore Lossos, the trial's lead investigator, noted the importance of achieving a complete response for positive outcomes in MZL and expressed optimism about expanding the trial to more sites.
MZL is a rare form of non-Hodgkin lymphoma with limited FDA-approved therapies, representing an area of significant unmet medical need. ADC Therapeutics' Chief Medical Officer, Mohamed Zaki, MD, PhD, highlighted the company's intention to pursue a regulatory pathway based on the trial's results.
Ameet Mallik, CEO of ADC Therapeutics, remarked on the potential opportunity for ZYNLONTA in the treatment setting for this rare disease, given the encouraging initial data. ZYNLONTA, a CD19-directed antibody drug conjugate, is approved by the FDA and EMA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
The information in this article is based on a press release statement from ADC Therapeutics SA.
InvestingPro Insights
ADC Therapeutics SA (NYSE:ADCT) has shown a remarkable performance in the stock market with a significant 150.0% return over the last year, indicating strong investor confidence which may be buoyed by recent clinical successes. The company's recent Phase 2 clinical trial results for ZYNLONTA® could potentially enhance its market position, as evidenced by the 195.18% year-to-date price total return, reflecting the market's positive reaction to the company's operational milestones.
Despite these promising developments, InvestingPro data suggests that ADC Therapeutics is facing financial challenges, with a negative gross profit margin of -80.72% for the last twelve months as of Q4 2023. This could be a point of concern for investors, as it indicates that the cost of goods sold exceeds the company's revenue. Moreover, the company's negative P/E ratio of -1.68 signals that it is not currently generating profits, a situation that analysts do not expect to change within this year.
InvestingPro Tips for ADC Therapeutics highlight the company's volatility and cash burn issues, which investors should consider when evaluating the stock. On the positive side, the company's liquid assets exceed its short-term obligations, suggesting a degree of financial stability in the near term. For those interested in deeper analysis, there are 10 additional InvestingPro Tips available for ADC Therapeutics, which can be accessed with the coupon code PRONEWS24 for an extra 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.